Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Bay, Jacques-Olivier  [Clear All Filters]
2013
Penel N, Ray-Coquard I, Bal-Mahieu C, Chevreau C, Le Cesne A, Italiano A, Bompas E, Clisant S, Baldeyrou B, Lansiaux A, et al. Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Target Oncol. 2013.
2015
de Fontbrune FSicre, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay J-O, Neven B, Moussi J, Simon L, et al. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC. Transplantation. 2015.
2016
Cornillon J, Balsat M, Cabrespine A, Tavernier-Tardy E, Hermet E, Mulliez A, Augeul-Meunier K, Guyotat D, Bay J-O. Impact of ATG Dose on the Outcome of Patients Undergoing Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies. Acta Haematol. 2016;136(4):193-200.
2019
Jaimes-Albornoz D, Mannone L, Nguyen-Quoc S, Chalandon Y, Chevallier P, Mohty M, Meunier M, Robin M, Ledoux M-P, Guillerm G, et al. Allogeneic stem cell transplantation in therapy-related myelodysplasia after autologous transplantation for lymphoma: a retrospective study of the SFGM-TC. Biol Blood Marrow Transplant. 2019.
Balsat M, Pillet S, Tavernier E, Cacheux V, Escuret V, Moluçon-Chabrot C, Augeul-Meunier K, Mirand A, Regagnon C, Tinquaut F, et al. Human Herpesvirus 6 Infection after Autologous Stem Cell Transplantation: A Multicenter Prospective Study in Adult Patients. J Infect. 2019.
2022
Devillier R, Galimard J-E, Labopin M, Blaise D, Raiola AMaria, Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022.
2023
Rey G, Daguenet E, Bonjean P, Devillier R, Fegueux N, Forcade E, Srour M, Chevallier P, Robin M, Suarez F, et al. Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC. Bone Marrow Transplant. 2023.
Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. Nat Med. 2023.
Dougé A, Ravinet A, Corriger A, Cabrespine A, Wasiak M, Pereira B, Sokol H, Nguyen S, Bay J-O. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study). BMJ Open. 2023;13(5):e068480.
Michel C, Robin M, Morisset S, Blaise D, Maertens J, Chevalier P, Castilla-Llorente C, Forcade E, Ceballos P, Yakoug-Agha I, et al. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. Bone Marrow Transplant. 2023.
Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023.
Dougé A, Vituret C, Carraro V, Parry L, Coudy-Gandilhon C, Lemal R, Combaret L, Maurin A-C, Averous J, Jousse C, et al. Temporal regulation of transgene expression controlled by amino acid availability in human T cells. HLA. 2023.
2024
Lacan C, Lambert J, Forcade E, Robin M, Chevallier P, Loron S, Bulabois C-E, Orvain C, Ceballos P, Daguindau E, et al. Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry. J Hematol Oncol. 2024;17(1):2.
Dougé A, Caux C, Bay J-O. [Cell therapy in all its forms]. Bull Cancer. 2024.